An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK)

Nuclear Medicine and Biology

Volumn 33, Issue 5, 2006, Pages 677-683

  Lee, Yun Sang ^a,b   Jeong, Jae Min ^a   Kim, Hyung Woo ^a,b   Chang, Young Soo ^a,b   Kim, Young Joo ^a   Hong, Mee Kyung ^a   Rai, Ganesha B ^a   Chi, Dae Yoon ^c   Kang, Won Jun ^a   Kang, Joo Hyun ^a   Lee, Dong Soo ^a   Chung, June Key ^a   Lee, Myung Chul ^a   Suh, Young Ger ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Inha University   (South Korea)

Author keywords

v 3 Integrin; 18F; 18F Fluorobenzaldehyde; HYNIC; Peptide labeling; RGD peptide

Indexed keywords

4 FLUOROBENZALDEHYDE F 18; 4' FLUOROBENZYLIDENEHYDRAZONE 6 NICOTINAMIDE CYCLIC ARGINYLGLYCYLASPARTIC ACID DEXTRO TYROSYLLYSINE F 18; 6 HYDRAZINONICOTINAMIDE CYCLIC ARGINYLGLYCYLASPARTIC ACID DEXTRO TYROSYLLYSINE; ARGINYLGLYCYLASPARTIC ACID; BENZALDEHYDE DERIVATIVE; CYCLIC ARGINYLGLYCYLASPARTIC ACID DEXTRO TYROSYLLYSINE I 125; HYDRAZONE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID; 6-HYDRAZINOPYRIDINE-3-CARBOXYLIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; DIAGNOSTIC AGENT; FLUORINE; HYDRAZINE DERIVATIVE; NICOTINIC ACID DERIVATIVE; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PURIFICATION; DRUG PURITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG UPTAKE; FEMORAL ARTERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HINDLIMB; INJECTION; ISOTOPE LABELING; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; RADIOCHEMISTRY; RECEPTOR AFFINITY; TAIL; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COMPARATIVE STUDY; EVALUATION; ISCHEMIA; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SKELETAL MUSCLE; SYNTHESIS; TISSUE DISTRIBUTION; VASCULARIZATION;

ANIMALS; FLUORINE RADIOISOTOPES; HYDRAZINES; HYDRAZONES; INTEGRIN ALPHAVBETA3; ISCHEMIA; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MUSCLE, SKELETAL; NICOTINIC ACIDS; OLIGOPEPTIDES; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33745809823     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.04.004     Document Type: Article

References (41)

1. 3 during angiogenesis. J Clin Invest 98 (1996) 426-433
2. Byzova T.V., Rabbani R., D'Souza S.E., and Plow E.F. Role of integrin alpha(v)-beta3 in vascular biology. Thromb Haemost 80 (1998) 726-734
3. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103 (1999) 1237-1241
4. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
5. Ruoslahti E., and Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 238 (1987) 491-497
6. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96 (1995) 1815-1822
7. 3 integrin monoclonal antibody. Biochim Biophys Acta 1336 (1997) 445-454
8. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
9. 3 integrin in human melanoma cells. Eur J Cancer 36 (2000) 410-422
10. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40 (1999) 1061-1071
11. 90Y-labeled DTPA-biomolecule conjugates. Bioconjug Chem 12 (2001) 84-91
12. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42 (2001) 326-336
13. 3 integrin binding peptides in a nude mouse model. Cancer Res 62 (2002) 6146-6151
14. 3 integrin for tumor imaging. Bioconjug Chem 13 (2002) 561-570
15. 64Cu-labeled RGD peptide. Bioconjug Chem 15 (2004) 41-49
16. 18F-labeled RGD and octreotide analogs. J Nucl Med 45 (2004) 892-902
17. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31 (2004) 179-189
18. Kim J.S., Lee K.C., Lee B.C., Moon B.S., Song H.J., Chun K.S., et al. Synthesis of fluorine-18 labeled glucose-Lys-Arg-Gly-Asp-D-Phe as a potential tumor imaging agent. J Label Compd Radiopharm 48 (2005) S289
19. Okarvi S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 28 (2001) 929-938
20. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol 27 (2000) 103-112
21. 18F]GBR-13119. J Label Compd Radiopharm 27 (1989) 823-838
22. 18F]fluorobenzoate. Nucl Med Biol 19 (1992) 275-281
23. Wester H.J., Hamacher K., and Stocklin G. A comparative study of n.c.a fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 23 (1996) 365-372
24. 18F]fluorophenacyl bromide for radiolabeling of proteins and peptides. Appl Radiat Isot 48 (1997) 907-916
25. 18F]fluorobenzyl halides. Appl Radiat Isot 52 (2000) 87-92
26. Vries E.F.J., Vroegh J., Elsinga P.H., and Vaalburg W. Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. Appl Radiat Isot 58 (2003) 469-476
27. 18F using a hydrazone-formation method. Bioconjug Chem 16 (2005) 1329-1333
28. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., and Isner J.M. Mouse model of angiogenesis. Am J Pathol 152 (1998) 1667-1679
29. v integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med 46 (2005) 472-478
30. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31 (2004) 11-19
31. Kouns W.C., Kirchhofer D., Hadvary P., Edenhofer A., Weller T., Pfenninger G., et al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 80 (1992) 2539-2547
32. Pytela R., Pierschbacher M.D., Argraves S., Suzuki S., and Ruoslahti E. Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol 144 (1987) 475-489
33. Abrams M.J., Juweid M., tenKate C.I., Schwartz D.A., Hauser M.M., Gaul F.E., et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31 (1990) 2022-2028
34. 99mmTc-protein conjugates. Bioconjug Chem 2 (1991) 333-336
35. 111In IgG. Nucl Med Biol 22 (1995) 643-648
36. 3]octreotide. Bioconjug Chem 10 (1999) 431-438
37. Greenland W.E.P., Howland K., Hardy J., Fogelman I., and Blower P.J. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-E-(Hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem 46 (2003) 1751-1757
38. King T.P., Zhao S.W., and Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry 25 (1986) 5774-5779
39. 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. Arch Pharm Res 27 (2004) 961-967
40. Silva A.G., Zapata-Sudo G., Kummerle A.E., Fraga C.A.M., Barreiro E.J., and Sudo R.T. Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg Med Chem 13 (2005) 3431-3437
41. Uppadine L.H., Gisselbrecht J.-P., Kyritsakas N., Nattinen K., Rissanen K., and Lehn J.-M. Mixed-valence, mixed-spin-state, and heterometallic [2×2] grid-type arrays based on heteroditopic hydrazone ligands: synthesis and electrochemical features. Chem Eur J 11 (2005) 2549-2565